ANNUAL REPORT FY2025 15 Financial summary Financially, Nyrada continued to apply disciplined capital management, ensuring sufficient funding for its clinical and research programs while maintaining lean operations. As of 30 June 2025, the Company’s cash balance stood at AU$2.93 million. During the year, Nyrada successfully raised AU$3.45 million (before costs) through a fully subscribed placement and a Securities Purchase Plan, with participation from Non-Executive Directors approved at the Extraordinary General Meeting held in April 2025. The Company also benefited from government support, receiving AU$1.24 million under the Commonwealth Government’s R&D Tax Incentive scheme in December 2024. As Nyrada moves into FY2026, it does so with strong clinical momentum, compelling scientific validation, and a clear strategic roadmap toward initiating a Phase IIa clinical trial. With final Phase I results imminent and additional indications under evaluation, the Company is wellpositioned to unlock further value for shareholders and continue advancing the clinical development of Xolatryp. Liquidity and capital resources Nyrada ended the financial year with cash of $2,930,601 and anticipates receiving an Research and Development tax incentive refund of $2,155,853 for FY2025 following 30 June 2025, thus further boosting capital resources. Matters subsequent to the end of the financial year On 4 August, 433,333 CDIs were issued as a result of options exercised at $0.135 per CDI. On 4 August 2025, 105,000 CDIs were issued for the provision of services at an agreed rate of $0.24 per CDI. On 4 August 2025, the Consolidated entity announced it received firm commitments for a placement of 27.5million Chess Depositary Instruments (CDIs), raising $8.25 million in new equity capital from new and existing institutional, professional and sophisticated investors (Placement). The Placement issue price was $0.30 per CDI. On 11 August 2025, 26,200,000 CDIs were issued at $0.30 per CDI in connection with the Placement announced on 4 August 2025. On 11 August 2025, 150,000 CDIs were issued as a result of options exercised at $0.135 per CDI. Future developments, prospects, and business strategies Disclosure of information regarding likely developments in the operations of the Company in future financial years and the expected results of those operations is likely to result in unreasonable prejudice to the Company. Information on future developments, prospects, and business strategies have only been referred to in the Chair’s Letter and CEO Report. For further information on the Company’s business strategies and material risks, refer also to the Prospectus which is available on the Company website or ASX Announcements. Environmental regulation The Consolidated Entity is not subject to any significant environmental regulation under Australian Commonwealth or State law.
RkJQdWJsaXNoZXIy MjE2NDg3